Press Releases

CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated,

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced

Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interventions CareDx Symposia Feature Latest Advancements Including XenoSure and XenoMap SOUTH SAN

CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and

CareDx’s TxAccess Digital Platform Helps Move Pre-Transplant Patients to Transplant Faster SOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated,

Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced

New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated,

Represents World’s First Surveillance Solutions for Investigational Use in Xenotransplantation Research and Post-Xenotransplant Clinical Monitoring SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,